Ibrutinib

Olpha manufactures high-quality Ibrutinib API for pharmaceutical companies worldwide. Based in Europe, Olpha offers Ibrutinib Form A and co-crystal BA for development, validation, and commercial manufacturing, with reliable global supply.

Therapeutic Categories
Antineoplastic agents
Pharmacopoeia
CAS No.
[ 936563-96-1]
Stage
C - Commercial

Ibrutinib is used primarily in the treatment of B-cell malignancies, including:

  • Mantle cell lymphoma (MCL): Used in previously untreated patients in combination with other therapies and as monotherapy in patients whose disease has relapsed or is refractory to previous treatment.

  • Chronic lymphocytic leukaemia (CLL): Used in both previously untreated and previously treated patients, either alone or in combination with medicines such as rituximab, obinutuzumab, bendamustine, or venetoclax.

  • Waldenström’s macroglobulinaemia (WM): Used as monotherapy or in combination with rituximab.

Cooperate with Olpha

Media

For media relations and partnerships

Business

For distributors and business partners

Social Initiatives

For social causes and potential projects

Careers

For open positions and career opportunties

Attention!

Information on prescription medications should only be viewed by healthcare professionals.

Are you a health care worker?